CIDP therapy reshapes around FcRn antagonist class entry
Efgartigimod CIDP indication, follow-on FcRn antagonist programs, and structured maintenance protocols are reshaping chronic inflammatory demyelinating polyneuropathy management.
Chronic inflammatory demyelinating polyneuropathy (CIDP) has been an IVIG, plasma exchange, and corticosteroid category for years. Efgartigimod (FcRn antagonist) carries CIDP approval, follow-on FcRn antagonist programs in CIDP are in late-stage trials, and structured maintenance protocols are formalising. The category is acquiring a real biologic prescribing tier, with the maintenance question driving long-term commercial reach.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
Related
- SnapshotAcute ischemic stroke therapy reference (2026)
- ExplainedWhat is spasticity?
- SnapshotSpasticity therapy reference (2026)